Tarsus CCO acquires 26,482 shares via RSU vesting

Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala acquired 26,482 shares of common stock on March 15, 2026 through the settlement of vested Restricted Stock Units granted under the company’s 2020 Stock Plan.

Rhea-AI Filing Summary

Tarsus Pharmaceuticals Chief Commercial Officer Aziz Mottiwala acquired 26,482 shares of common stock on March 15, 2026 through the settlement of vested Restricted Stock Units granted under the company’s 2020 Stock Plan. Each RSU converts into one share of common stock at no cash exercise price.

Following these transactions, Mottiwala directly holds 74,536 shares of Tarsus common stock. This total includes 497 shares acquired under the company’s Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025, reflecting ongoing equity-based compensation rather than open-market buying or selling.

Insider Trade Summary

26,482 shares exercised/converted

Exercise 5 txns

Insider Mottiwala Aziz

Role Chief Commercial Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	4,790	$0.00	$0.00
Exercise	Restricted Stock Units	8,148	$0.00	$0.00
Exercise	Restricted Stock Units	8,020	$0.00	$0.00
Exercise	Restricted Stock Units	5,524	$0.00	$0.00
Exercise	Common Stock	26,482	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 40,762 contracts (Direct); Common Stock — 74,536 shares (Direct)

Footnotes (7)

1. F1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").
2. F2. Includes 497 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025.
3. F3. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.
4. F4. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.
5. F5. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
6. F6. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.
7. F7. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Tarsus Pharmaceuticals (TARS) disclose about Aziz Mottiwala’s recent equity transactions?

Tarsus Pharmaceuticals reported that Chief Commercial Officer Aziz Mottiwala acquired 26,482 common shares on March 15, 2026 through settlement of vested Restricted Stock Units. These transactions reflect equity compensation vesting rather than open-market stock purchases or sales.

How many Tarsus Pharmaceuticals (TARS) shares does Aziz Mottiwala now hold?

After the March 15, 2026 transactions, Aziz Mottiwala directly holds 74,536 shares of Tarsus common stock. This amount includes 497 shares previously acquired under the company’s Employee Stock Purchase Plan in 2025, according to the disclosure footnotes.

Were Aziz Mottiwala’s Tarsus (TARS) transactions open-market buys or sales?

The reported activity did not involve open-market buys or sales. Instead, Aziz Mottiwala acquired shares through the exercise and settlement of vested Restricted Stock Units, which convert into common stock at no cash exercise price under Tarsus’s 2020 Stock Plan.

What role did Restricted Stock Units play in the Tarsus (TARS) Form 4 filing?

The Form 4 shows multiple Restricted Stock Unit settlements, where each RSU represented a contingent right to receive one Tarsus common share. As RSUs vested under grants from 2022 to 2025, they were settled into 26,482 common shares for Aziz Mottiwala.

How are Aziz Mottiwala’s RSU grants at Tarsus (TARS) structured over time?

Footnotes explain that RSU grants from 2022, 2023, 2024 and 2025 vest in 25% annual installments around March 15 of four consecutive years, subject to continuous service. The March 15, 2026 settlements reflect vesting under these multi-year schedules.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/17/2026 - 04:32 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mottiwala Aziz

(Last) (First) (Middle)

C/O TARSUS PHARMACEUTICALS, INC.

15440 LAGUNA CANYON ROAD, SUITE 160

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tarsus Pharmaceuticals, Inc. [ TARS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/15/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/15/2026		M		26,482	A	(1)	74,536(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(3)	03/15/2026		M			4,790	(4)	(4)	Common Stock	4,790	$0	0	D
Restricted Stock Units	(3)	03/15/2026		M			8,148	(5)	(5)	Common Stock	8,148	$0	8,148	D
Restricted Stock Units	(3)	03/15/2026		M			8,020	(6)	(6)	Common Stock	8,020	$0	16,040	D
Restricted Stock Units	(3)	03/15/2026		M			5,524	(7)	(7)	Common Stock	5,524	$0	16,574	D

Explanation of Responses:

1. The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs").

2. Includes 497 shares acquired under the Issuer's Employee Stock Purchase Plan on June 30, 2025 and December 31, 2025.

3. Each Restricted Stock Unit represents a contingent right to receive one share of the Company's common stock.

4. RSUs granted on March 9, 2022, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs vested on March 15th of each of 2023, 2024, 2025 and 2026.

5. RSUs granted on March 8, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.

6. RSUs granted on March 7, 2024, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2025, 2026, 2027 and 2028, subject to the Reporting Person's continuous service.

7. RSUs granted on March 5, 2025, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on March 15th of each of 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service.

Remarks:

	/s/ Jeffrey Farrow, Attorney-in-Fact	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.